The effect of selective histamine H1-receptor antagonists on cardiovascular system;Wpływ leków przeciwhistaminowych drugiej generacji na serce

Pneumonologia i Alergologia Polska

Volumn 69, Issue 3-4, 2001, Pages 217-226

  Grzelewska Rzymowska, I ^a   Pietrzkowicz, M ^a   Gorska M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

H1 receptors antagonists; Potassium channels of heart; Torsades de pointes

Indexed keywords

ASTEMIZOLE; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; LORATADINE; NORASTEMIZOLE; POTASSIUM CHANNEL; POTASSIUM ION; TERFENADINE;

ARRHYTHMOGENESIS; DRUG SAFETY; HEART CONDUCTION; HUMAN; LONG QT SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; QT INTERVAL; REVIEW; TORSADE DES POINTES;

ANIMALS; AREA UNDER CURVE; ASTEMIZOLE; BUTYROPHENONES; ELECTROCARDIOGRAPHY; HEART; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; PIPERIDINES; TACHYCARDIA; TERFENADINE; TORSADES DE POINTES;

EID: 0034906328     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Three month evaluation of electrocardiographic effects of loratadine in humans
2. Lack of interaction between mizolastine and diltiazem in healthy volunteers
3. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis
4. Regulation of potassium channels by nonsedating antihistamines
5. Evaluation of the pharmacokinetics and electrocardiographiv pharmacokinetics of loratadine with concomitant administration of cimetidine
6. Evaluation of pharmacokinetic and electrocardiographe parameters following 10 days of concomitant administration of loratadine with ketoconazole
7. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations
8. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies
9. Cardiac safety of azelastine following 8 weeks of intranasal administration
10. Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5
11. + currents in cardiac cells: Comparison with terfenadine
12. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist
13. Interaction study between mizolastine, a new H1-antihistamine, and erythromycin
14. Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers
15. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity
16. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
17. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine
18. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children
19. Comparative effects of loratadine and terfenadine on cardiac K+ channels
20. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity
21. Cardiovascular profile of loratadine
22. Ketoconazole enhances the QTc interval prolongation effects of the nonsedating antihistamines terfenadine and ebastine in an experimental animal model
23. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects
24. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects
25. + channel family by ebastine
26. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart
27. Long term maintenance of symptoms relief in patients suffering from chronic urticaria (CU) treated with mizolastine
28. Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers
29. A review of the cardiac systemic side-effects of antihistamines: Ebastine
30. Cardiovascular safety of fexofenadine HCl
31. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart
32. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine
33. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine
34. Lack of electrocardiographic effects of cetirizine in healthy humans
35. Prospektywne, długofalowe badanie oceniaja̧ce bezpieczeństwo stosowania u malych dzieci z atopowym zapaleniem skóry cetyryzyny - Antagonisty receptora H1
36. The therapeutic index of newer H1-recpetor antagonists
37. + channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines
38. Lack of cardiac effects of mizolastine: A pooled ECGs analysis of four double blind studies
39. + current similar to Kv1.5 cloned channel currents
40. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome
41. Mechanism of the cardiotoxic actions of terfenadine
42. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects
43. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers
44. The current cardiac safety situation with antihistamines